Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Revenue: 2011-2025

Historic Revenue for Catalyst Pharmaceuticals (CPRX) over the last 7 years, with Sep 2025 value amounting to $148.4 million.

  • Catalyst Pharmaceuticals' Revenue rose 15.31% to $148.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $578.2 million, marking a year-over-year increase of 25.56%. This contributed to the annual value of $491.7 million for FY2024, which is 23.49% up from last year.
  • According to the latest figures from Q3 2025, Catalyst Pharmaceuticals' Revenue is $148.4 million, which was up 1.25% from $146.6 million recorded in Q2 2025.
  • Over the past 5 years, Catalyst Pharmaceuticals' Revenue peaked at $148.4 million during Q3 2025, and registered a low of $30.2 million during Q1 2021.
  • Over the past 3 years, Catalyst Pharmaceuticals' median Revenue value was $122.7 million (recorded in 2024), while the average stood at $120.6 million.
  • Data for Catalyst Pharmaceuticals' Revenue shows a peak YoY spiked of 98.12% (in 2023) over the last 5 years.
  • Quarterly analysis of 5 years shows Catalyst Pharmaceuticals' Revenue stood at $38.3 million in 2021, then soared by 58.60% to $60.8 million in 2022, then soared by 81.98% to $110.6 million in 2023, then grew by 28.26% to $141.8 million in 2024, then rose by 15.31% to $148.4 million in 2025.
  • Its last three reported values are $148.4 million in Q3 2025, $146.6 million for Q2 2025, and $141.4 million during Q1 2025.